Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.
19
2
B
COVID
CoV
SARS
cell depletion
convalescent plasma
immunodeficiency
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
09 04 2022
09 04 2022
Historique:
received:
15
06
2021
pubmed:
23
7
2021
medline:
13
4
2022
entrez:
22
7
2021
Statut:
ppublish
Résumé
Twenty-five B-cell-depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.
Identifiants
pubmed: 34293119
pii: 6325623
doi: 10.1093/cid/ciab647
pmc: PMC8406883
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Banques de données
ClinicalTrials.gov
['NCT04375098']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1271-1274Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Clin Transl Immunology. 2021 May 16;10(5):e1285
pubmed: 34026115
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Science. 2021 Feb 26;371(6532):
pubmed: 33361116
JAMA Oncol. 2021 Jun 17;:
pubmed: 34137799
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb 11;:
pubmed: 33741148
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220